SUMMARY The effect that synthetic steroid components of different oral contraceptives have on the assay system for measurement of sex hormone binding globulin (SHBG)-binding capacity, has been examined. Interference with the assay was not demonstrable at therapeutic levels of the drugs. d-Norgestrel was the only steroid studied which bound to SHBG with an affinity comparable to the endogenous sex hormones; it also tended to decrease SHBG-binding capacity, whereas preparations containing low levels of norethisterone increased the binding capacity. We suggest that measurement of changes in SHBG-binding capacity in subjects taking oral contraceptives may prove useful in indicating changes in sex hormone balance, particularly in view of the well-recognised side-effect of these drugs.
Sex hormone binding globulin (SHBG) is the major carrier protein in blood for testosterone and 17~ oestradiol. Testosterone binds to SHBG with high affinity, and an inverse correlation between free testosterone and SHBG levels can be demonstrated. However, no such relationship exists between free 17~-oestradiol concentration and SHBG, since 17~-oestradiol binds to SHBG with only about one-third of the affinity of testosterone, although it binds extensively to albumin. Only the unbound fractions of these hormones are physiologically active.
Changes in blood levels of SHBG can be induced by endogenous sex hormones and also by synthetic steroids.l " Any factor that raises SHBG levels, such as a rise in the circulating level of unbound 17r> oestradiol, will cause a differential fall in unbound testosterone, leading to increased oestrogenicity. Conversely, any factor that lowers SHBG levels, such as an increase in testosterone production, will cause a differential rise in unbound testosterone relative to oestradiol and lead to increased androgenicity. The level of SHBG in the blood is thus an important factor in determining the sex hormone balance of an individual.
We have examined the effect that certain synthetic steroids, constituents of seven commonly prescribed oral contraceptives, have on the assay of SHBG. The blood SHBG-binding capacity of 40 women receiving different oral contraceptives has been measured and the relationship to our in vitro binding experiments has been examined.
Material and methods

SUBJECTS
Forty women, who between them were receiving seven different oral contraceptives, were studied. A serum sample was obtained from each subject when she came to her general practitioner for a repeat prescription, and was stored at -20 cC until assayed. In this manner we ensured that each patient had been receiving her therapy for at least two months. The number of patients taking each preparation is shown in Table 1 .
REAGENTS
Natural steroids: 17r>oestradiol, testosterone, 51X-dihydrotestosterone (DHT), cortisol, and progesterone obtained from Sigma (London) Chemical Three different pools of serum samples were assayed 20 times over a period of five months, and betweenassay precision values were determined; CVs of ±1l'5%, ±6'3%, and ±4'8%, were obtained from pools with mean SHBG-binding capacities of 34 nmol/I, 82 nrnol/l, and 503 nrnol/l, respectively.
TEST FOR INTERFERENCE WITH SHBG ASSAY
Removal of steroids from serum samples
Ten samples from women each taking one of a variety of oral contraceptive preparations were treated with charcoal to remove the endogenous and exogenous steroids. 25 rng Norit A charcoal (Sigma, London) was mixed with 500 !LI serum for 1 hour at room temperature. The samples were centrifuged twice at 2000 rpm for 15 minutes to remove all the charcoal. The samples were assayed for SHBGbinding capacity before and after the charcoal treatment.
Addition of steroids
Duplicate samples of ethanolic solutions of the synthetic steroids used were dried down in tubes to give final concentrations of 2 ng and 20 ng steroid per tube. To each pair of tubes 25 !LI of the pooled serum and 475 !LI of the appropriate DHT solution was added and the SHBG level was determined.
Each synthetic steroid concentration was tested with the 'male', 'female', and 'pregnancy' SHBG pools.
BINDING STUDIES
Binding to SHBG at 4°C and 37°C A 1 in 20 dilution of LPS was made in PBS. Using this binding solution, a 1 in 80 dilution of the stock 3H-DHT solution (24 ngjrnl) was made, resulting in a final concentration of 3H-DHT of 0·15 ng/500!L1. Stock solutions of the steroids were diluted in absolute ethanol to give concentrations ranging from 1 to 10 000 ng/100 !Ll. Duplicate 100 !LI aliquots of the solutions were dried down in glass tubes at 50 G e under a stream of N 2 • 500!LI of the LPS/label solution was added and the dried residues were redissolved by vortexing. Tubes containing only LPS/label solution for determining the maximum binding, and tubes containing 10 000 ng DHT for determining minimum binding, were set up in quadruplicate to enable the percentage binding to be calculated. After incubation for 1 hour at 4°C, 500 fll saturated ammonium sulphate was added to all the tubes with immediate mixing. After centrifugation at 2000 rpm for 30 minutes the supernatant was decanted into scintillation vials. 10 ml NE-26O scintillant was added, and the radioactivity was counted in a scintillation counter. The procedure was repeated with incubation at 37°C. Binding to cortisol-binding globulin at 37°C Binding to cortisol-binding globulin (CBG) was investigated only at 37°C since this was considered to be nearer physiological conditions. The LPS/label solution used was a 1 in 10 dilution of LPS in PBS containing 5· 3 pg 3H-eortisol/500 fll of solution.
Ethanolic solutions of the steroids tested were dried down as before, 500 III of the LPS/label solution was added, and the tubes were vortexed to redissolve the dried residue. 'Total' and 'blank' tubes were also set up; the 'total' tubes contained the LPS/label solution only; 500 III PBS was added after incubation. 'Blank' tubes contained label only. After incubation at 37°C for 30 minutes, 500 fll dextran-eoated charcoal suspension (0'25 g Norit A charcoal, 0·025 g Dextran T-70/100 ml PBS) was rapidly added to all tubes except 'total'. Charcoal must be used here for the separation as ammonium sulphate precipitates only 15% of CBG.3 The tubes were mixed and immediately centrifuged to minimise the binding loss, and the supernatants were decanted and counted as before.
Results
INTERFERENCE BY SYNTHETIC STEROIDS IN SHBG ASSAY
The SHBG-binding capacities determined in serum from women on contraceptive therapy before and after charcoal treatment to remove steroids are shown in Table 2 .
Charcoal treatment did not produce any change in the SHBG-binding capacity in these specimens. Table 3 shows the apparent SHBG-binding capacities for the three pools when 2 ng or 20 ng steroid was added to 25 III serum. While interference from the three progestagens (d-norgestrel, norethisterone, and lynestrenol) was probably significant at the 20 ng level, this is equivalent to an excessively high serum level of 80 Ilg/1OO mI; 2 ng of added steroid corresponds to a level of 8 Ilg/1OO ml, and levels even this high are unlikely to be approached with any of the BINDING STUDIES Binding to SHBG In Fig. 1 the percent displacement curves for the steroids tested in the 3H-DHT/LPS system at 40C are shown, while Fig. 2 shows the curves at 370C. The use of 3H-DHT as the tracer has been demonstrated to be specific for SHBG binding." DHT does not bind to CBG, part of which is precipitated by 50% ammonium sulphate. Albumin partially binds DHT; however, this complex is not precipitated by 50 % ammonium sulphate. The SHBG-DHT complex is not precipitated by 50 %ammonium sulphate.
The SHBG-DHT complex is completely precipitated without dissociation. The binding of 3H-DHT in the absence of exogenous steroids was about 60 %.
At either temperature d-norgestrel binds strongly to SHBG, more so than 17(3-oestradiol. Norethisterone binds to SHBG but with a lesser affinity than the natural sex hormones. The displacing power of 
3H-DHT from SHBG in assay system
Binding to eBG at 37°e Table 5 shows the percentage displacement of 3H_ cortisol/LPS system. It may be seen that, apart from cortisol and progesterone, the only steroid that has any significant displacement activity is testosterone. Therefore CBG binding plays no part in the reactions of the synthetic steroids.
SHBG LEVELS IN WOMEN TAKING ORAL
CONTRACEPTIVES
We had determined our normal range as 36-76 nmol/I (mean 56 nmol/I, SD x 10 nmol/!) from previous studies on 22 normal female subjects who were neither pregnant nor taking oral contraceptives. As many workers" 6 had found no consistent change in SHBG-binding capacities during the menstrual cycle, the sampling date was not considered significant. There was no variation with age between the menarche and the menopause (SMB, personal observation) . The levels of SHBG-binding capacity determined in women taking oral contraceptives are shown in Fig. 3 Steroid added (ng) Fig. 2 Displacement curves in the 3H-DHT/late pregnancy serum system at 37"C: (I) 
d-norgestrel and norethisterone is markedly increased by increasing the temperature of the assay system from 4°C to 37°C. Testosterone shows only a marginal increase, however, as shown in Table 4 . The other synthetic steroids studied, Iynestrenol, ethinyloestradiol, and mestranol, have more oestrogenic-type structures and bind with extremely low affinities.
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Discussion longer prescribed) decreased SHBG levels. 21o Studies have also been made of the effects of combined-type oral contraceptives containing the standard dose of 50 !Jog ethinyloestradiol. The addition of increasing amounts of Iynestrenol or d-norgestrel to a dose of 50 !Jog ethinyloestradiol was found to decrease the oestrogen-induced rise of SHBGI0 and at higher concentration (2'5 mg Iynestrenol or O'25 mg d-norgestrel) totally to neutralise it. 10 11 These findings were contradicted by another study, which suggested that a combination of d-norgestrel or lynestrenol with 50 !Jog ethinyloestradiol raised SHBG levels, although the rise was less with d-norgestrel. 9 Our results confirm studies suggesting that progestagens alone, particularly d-norgestrel, lower SHBG levels, and that they can block the effect of oestrogen on SHBG. 2 d-Norgestrel has been recognised as having significantly different actions from the other 19-nor testosterone derivatives as it seems to be a far more potent oestrogen antagonist.P 12 Studies on the effect of d-norgestrel and norethindrone in combination with ethinyloestradiol on other serum proteins indicated'! that d-norgestrel was quite effective at blocking oestrogen-induced changes in thyroidbinding globulin and haptoglobin. Norethindrone, on the other hand, had oestrogen-like effects on these proteins. d-Norgestrel is the only one of the synthetic steroids we tested which bound to SHBG with an affinity comparable to the endogenous androgens DHT and testosterone. This appears to provide evidence that d-norgestrel has androgenic activity due to its structure, since there is an apparent relation between the in vivo androgenic activity of steroids and their ability to bind to SHBG; the more potent the androgen, the greater its binding to SHBG.l It is likely that d-norgestrel exerts a direct effect to inhibit SHBG synthesis, as do the endogenous androgens.
The important role that SHBG has in sex hormone balance' 6 has not been taken into account in studies of hormone levels in women taking oral contraceptives.f 13 Indeed, it has been assumed that all oral contraceptives raise SHBG.8 It is difficult to interpret the observations of raised testosterone and DHT levels, which have been reported," 13 unless the variations in SHBG-binding capacity produced by different synthetic steroids are also taken into account. When SHBG levels are raised a rise in total testosterone may produce little or no change in the unbound fraction, whereas when the SHBG level falls or remains unchanged, rising total testosterone levels will lead to an increase in the unbound fraction and to increased androgenicity. Thus the androgenic changes, such as acne or -----.
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to fall below the normal female range (in some cases well into the male range) in half the women studied. This decrease, however, is not significant (t=1'21, 0·25>p>0·20). Decreasing the amount of dnorgestrel (Microgynon) may counteract this decrease in SHBG-binding capacity, but too few patients were studied for firm conclusions to be drawn. Fig. 3 Our results show that the SHBG-binding capacity in women taking combined type oral contraceptives depends on the balance between the oestrogen and progestagen components and also on the nature of the progestagen. Increasing the concentrations of progestagen can neutralise the effect that synthetic oestrogens have of raising the SHBG level. Furthermore, when the progestagen component is in excess, as it appears to be in Eugynon-30, the SHBG level may actually be lowered. We have demonstrated that these findings are not artefacts produced by the interference of the different synthetic steroids with the SHBG assay. Our results confirm the report by EI Makhzangy et al.
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It is well known that both endogenous and synthetic oestrogens raise blood levels of SHBGI 4 6 7 but the effect of synthetic progestagens has not been studied intensively, and the results have been rather conflicting. In one study'' neither lynestrenol nor d-norgestrel was shown to have any effect, while other studies have shown that Iynestrenol, d-norgestrel, and medroxyprogesterone acetate (no hirsutism, found in women taking low-dose oestrogen preparations containing d-norgestrel,14 16 may be ascribed to a depression of SHBG altering the hormone balance. This latter problem was also recognised by EI Makhzangy et al. 2 who studied SHBG levels in groups of women taking differing oral contraceptives. With one exception (Minovlar), these preparations were different from those taken by our subjects.
The 'ideal' oral contraceptive preparation would logically appear to be one which maintains the existing sex hormone balance, avoiding the undesirable effects of excess oestrogen administration on the one hand and excess androgenicity on the other. Since direct measurement of free hormone levels is destined to remain a research procedure, in our view, the measurement of SHBG-binding capacity would provide a simple parameter of whether the sex hormone balance was being maintained. If y-Iabelled-DHT were to become available this would become a practical screening procedure. Women vary a great deal in their requirement, and it may be that measurement of the SHBG-binding capacity before and during contraceptive therapy would be a better indication of whether the hormone balance in an individual woman was being altered and thus would provide a more logical means of prescribing than the present 'hit-or-miss' system. Our thanks to Dr A Clappen for providing us with the blood specimens and details of oral contraceptive therapy and to Miss P Murphy for typing this article.
